Suggested Remit: To appraise the clinical and cost effectiveness of semaglutide, within its marketing authorisation, in addition to a reduced calorie diet and increased physical activity, for the management of people with obesity or overweight with risk factors.
Status In progress
Process STA 2018
ID number 3850

Provisional Schedule

Expected publication 30 March 2022

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
05 March 2021 In progress. Topic is now in progress
25 November 2020 - 23 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance